CDK-Inhibitors as New Therapeutic Treatment for Human Bronchial Carcinoids
#1494
Introduction: Bronchial Carcinoids (BC) are still orphan of medical therapy. We previously demonstrated that 70% of primary BC cultures are sensitive to Everolimus (E), an mTOR inhibitor, while 30% are not. We also observed that in 2 human BC cell lines, the NCI-H720 (sensitive to E) and NCI-H727 (resistant to E), mTOR resistance may be linked to a differential cell cycle protein expression (CyclinD1/E, CDK2/4, p27kip1/p27kip1phospho-Ser10), which is higher in BC resistant to E as compared to sensitive ones, suggesting an impaired p27 function
Aim(s): Evaluate the response of BC immortalized cell lines and primary culture to Dinaciclib (D), a novel and potent CDK inhibitor
Materials and methods: We have assessed cell viability and apoptosis activation assay on BC primary cultures and immortalized cell lines, resistant or sensitive to mTOR inhibitor
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: BENFINI K
Authors: Benfini K, Gentilin E, Riva E, Di Pasquale C, Falletta S,
Keywords: Bronchial Carcinoid, Medical Therapy, mTOR Resistance, CDK inhibitors,
To read the full abstract, please log into your ENETS Member account.